TYSABRI
Google image searchProduct monograph
Active ingredient
natalizumab, 300 MG/15 ML
DIN: 02286386
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Schedule: Prescription / Schedule D
Company: BIOGEN CANADA INC
Date: 21-NOV-2006
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AG — Monoclonal antibodies (ATC, ATC/DDD)
- L04AG03 — NATALIZUMAB (ATC/DDD)
Reference brand drug: Tysabri
